NCPA's state government affairs team tirelessly tracks and engages with state legislation and regulation across the country, with our priorities including comprehensive PBM reform, PBM regulation enforcement, and Medicaid managed care reform. Here's a breakdown of our recent state government affairs activity relating to pharmacy reimbursement.
- Kansas Gov. Laura Kelly (D) signed into law SB 20, the Kansas Consumer Prescription Protection and Accountability Act. As previously reported, the bill creates strong audit protections and requires NADAC plus a professional dispensing fee in the commercial market for plans not subject to ERISA.
- NCPA submitted comments to the House Committee on Public Health in support of a package of PBM reform bills in Oklahoma. As previously reported, the bills included SB 2074, with a commercial market floor of NADAC plus the state Medicaid professional dispensing fee; SB 1500 addressing retroactive claims adjustments; and SB 2007 strengthening appeals processes.
- NCPA also submitted testimony in support of Minnesota SF 3299 ahead of a Senate Health and Human Services Committee meeting. The original bill focused on requiring NADAC plus the Medicaid professional dispensing fee in the commercial market but received an expansive amendment with many other PBM reform provisions and Medicaid issues that we are still reviewing.
- In alignment with pharmacy stakeholders in Illinois, NCPA filed a witness slip in a neutral position on an amended version of HB 1443, which would create a Prescription Drug Affordability Board with authority to establish Upper Payment Limits (UPLs) on drugs deemed unaffordable. Unlike in many other state bills, the amended version appears to hold pharmacies harmless by allowing for the professional dispensing fee and prohibiting wholesalers from selling drugs to pharmacies at a higher price than the UPL.
Please check out the NCPA state legislative tracking webpage, where you can see all the bills we are following and connect to our Advocacy page.
NCPA
